Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Exclusive: Germany's Bayer seeks animal health merger with Elanco - sources

Published 09/07/2019, 16:30
Updated 09/07/2019, 16:36
Exclusive: Germany's Bayer seeks animal health merger with Elanco - sources

Exclusive: Germany's Bayer seeks animal health merger with Elanco - sources

By Arno Schuetze and Pamela Barbaglia

FRANKFURT/LONDON (Reuters) - Bayer (DE:BAYGN) has approached U.S. drug firm Elanco Animal Health to discuss a possible combination of their pet-health businesses to create an industry giant, three sources familiar with the matter told Reuters.

The two companies are working with banks to ensure any merger would secure regulatory approval, the sources said, speaking on condition of anonymity.

Bayer has delayed the launch of an auction to private equity funds to clinch a bilateral deal with Elanco, the fourth-largest player in the animal health industry globally, the sources said.

The German drugmaker is under pressure to raise cash and boost its share price after its $63 billion (£50.5 billion) purchase of Monsanto (NYSE:MON).

Bayer ranks fifth in veterinary medicine. Aside from Elanco, its bigger rivals are former Pfizer (NYSE:PFE) unit Zoetis, unlisted Boehringer Ingelheim, which bought animal health assets from Sanofi (PA:SASY), and drugmaker Merck & Co.

Bayer Chief Executive Werner Baumann said in November his company would divest several assets including its animal health division, which analysts have said could fetch 6 billion to 7 billion euros.

The sources said discussions with Elanco were at an early stage and Bayer remained interested in receiving bids from private equity investors later this year.

An auction process was initially expected to start in June but Bayer would only dispatch information packages to prospective bidders towards the end of the summer, they said.

A Bayer spokesman said the firm was "progressing as planned" with efforts to separate the animal health business.

"After the strategic review of the possibilities, the main focus is on a sale," he said, adding Bayer continued to "consider all value-maximising options." He declined to comment on Elanco.

Elanco, which also declined to comment on any deal, offers more than 125 products to veterinarians and food animal producers in more than 90 countries.

The company, based in Greenfield in the U.S. state of Indiana, has a market value of $12 billion but it might struggle to finance an outright acquisition of Bayer's unit unless the German drugmaker decided to retain a stake in the combined entity, two sources said.

Elanco inherited a significant amount of debt from its previous owner Eli Lilly (NYSE:LLY), which spun it off last year.

As of December, it had about $2.5 billion of overall senior debt. In its annual report, it warned investors about the risk of failing to generate sufficient cash to service all its debts.

The sources said an all-cash sale to Elanco was unlikely, adding Bayer would need to keep a stake in the merged company to secure a deal.

Private equity firms may offer an easier exit for the German group but they are expected to value the company at a much lower price due to its declining business, the sources said.

Buyout funds had tried to take control of Elanco when it was part of Eli Lilly but the company opted for a more lucrative spin-off and listed the business in New York where it trades at about 20 times earnings.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.